非放射学中轴型脊柱关节炎患者抗TNF治疗前后的工作失能:瑞典南部基于人群的区域队列研究
本研究基于瑞典南部关节炎治疗组观察性研究,纳入75例未使用过生物制剂、符合ASAS中轴型脊柱关节炎标准且于2004-11年启动抗TNF治疗的非放射学中轴型脊柱关节炎(nr-axSpA)患者,链接瑞典社会保险局病假与残疾养老金数据,比较抗TNF启动前1年至后2年的工作损失天数,并纳入匹配人群参考。结果显示抗TNF治疗后2年内nr-axSpA组平均工作损失天数较参考人群的倍数从3.4显著降至1.9,效果见于病假,残疾养老金水平两组全程相似。结论提示抗TNF治疗与nr-axSpA工作失能持续改善相关,但随访结束时工作损失天数比例仍约为一般人群的两倍。
要点
- 抗TNF治疗与nr-axSpA患者2年内工作失能显著且持续改善相关。
- 工作损失天数较参考人群的倍数从3.4降至1.9,效果主要来自病假减少。
- 随访结束时工作损失天数比例仍约为一般人群的两倍。
核心结论
- 抗TNF治疗与nr-axSpA患者2年内工作失能显著且持续改善相关,但随访结束时工作损失天数比例仍约为一般人群的两倍。
研究设计与样本
- 基于瑞典南部关节炎治疗组观察性研究的区域队列,纳入75例17-62岁、符合ASAS中轴型脊柱关节炎标准且于2004-11年启动抗TNF的未使用过生物制剂nr-axSpA患者。
- 链接瑞典社会保险局病假与残疾养老金数据,覆盖抗TNF启动前1年至后2年,并纳入匹配人群参考以比较和校正 secular trends。
主要发现
- nr-axSpA患者启动治疗时中位年龄35岁、中位病程6年。
- 抗TNF启动后2年内,nr-axSpA组平均工作损失天数(含病假与残疾养老金)较参考人群的倍数从3.4显著降至1.9。
- 效果见于病假,残疾养老金水平两组全程相似。
临床怎么用
- 对符合ASAS中轴型脊柱关节炎标准且未使用过生物制剂的nr-axSpA患者,启动抗TNF治疗可能有助于减少病假相关的工作损失。
- 残疾养老金水平未见组间差异,工作失能改善主要应关注病假维度。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA). METHODS: Bionaïve nr-axSpA patients (n = 75), aged 17-62 years, fulfilling the Assessment of SpondyloArthritis international Society criteria for axial spondyloarthritis and starting anti-TNF treatment during 2004-11, were retrieved from the observational South Swedish Arthritis Treatment Group study. Patient information was linked to Swedish Social Insurance Agency data on sick leave and disability pension from 1 year before to 2 years after anti-TNF initiation. Matched population references were included for comparison and to adjust for secular trends. RESULTS: The nr-axSpA patients had a median age of 35 years and disease duration of 6 years at the start of treatment. During the 2 years after anti-TNF initiation, mean work-loss days (including both sick leave and disability pension) in the nr-axSpA group decreased significantly from 3.4 to 1.9 times more than among the population references. The effect was seen on sick leave, whereas disability pension levels remained similar in both groups throughout. CONCLUSION: Anti-TNF therapy in nr-axSpA was associated with a significant and sustained improvement of work disability over 2 years. However, the proportion of work-loss days remained almost twice as high as in the general population at the end of follow-up.
引用
- Wallman JK, Jöud A, Olofsson T, et al. Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology (Oxford). 2017. PMID: 28064208. doi:10.1093/rheumatology/kew473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。